Summary

The clinical trial supplies market is projected to reach USD 8.95 billion by 2031, up from USD 5.60 billion in 2026, at a 9.8% CAGR from 2026 to 2031. The market is expected to grow as the number of clinical trials rises, pharmaceutical and biotechnology R&D spending expands, and sponsors conduct more global, multicenter, decentralized, and adaptive studies. These changes increase demand for compliant sourcing, packaging and labeling, storage, temperature-controlled distribution, and real-time supply visibility. However, high costs for comparator procurement, cold-chain handling, country-specific labeling, storage, and transportation can increase trial budgets. Drug shortages, geopolitical disruption, complex import requirements, and inaccurate demand forecasts may also delay deliveries and increase product wastage. Logistics & distribution services accounted for the largest share, by service, in 2024 and continued to lead in 2025. Based on service, the clinical trial supplies market is segmented into sourcing & procurement; packaging & labeling; logistics & distribution; storage & retention; and other services, including biological sample management, destruction & waste management, and kit assembly. Logistics & distribution services held the largest share in 2025. This large share highlights the growing need to move investigational products, comparators, medical devices, and ancillary supplies across dispersed sites while maintaining chain of custody and product stability. Growth in biologics, vaccines, and cell & gene therapies is increasing demand for cold-chain, cryogenic, and ultra-low-temperature capabilities. Decentralized and direct-to-patient models further expand delivery destinations and require tighter coordination, monitoring, and returns management. The small molecules segment accounted for the largest share of the clinical trial supplies market, by type, in 2025. Based on type, the global clinical trial supplies market is segmented into small molecules, biologics, and medical devices. Small molecules accounted for the largest share of market revenue in 2025, supported by established manufacturing processes, cost-efficient production, ease of oral administration, and broad use across oncology, cardiovascular, neurological, and infectious diseases. Biologics include monoclonal antibodies, vaccines, cell & gene therapies, recombinant proteins, plasma-derived products, biosimilars, and peptides. Many of these products require refrigerated, frozen, or cryogenic handling and continuous temperature monitoring. Medical-device trials add requirements for component control, study-specific labeling, device accountability, and controlled distribution. The resulting range of dosage forms, stability profiles, and handling requirements sustains demand for specialized clinical supply partners with global quality and logistics capabilities. Asia Pacific is expected to grow at the highest CAGR in the clinical trial supplies market during the forecast period. The clinical trial supplies market is segmented into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Asia Pacific is estimated to record the highest CAGR during the forecast period, supported by expanding pharmaceutical and biopharmaceutical industries, competitive trial costs, favorable government policies, and a growing CRO base. The region is attracting more multinational trials, which increases demand for local depots, import and export support, country-specific labeling, comparator sourcing, and temperature-controlled delivery. North America accounted for the largest share of market revenue in 2025, supported by the adoption of decentralized trials and advanced cold-chain logistics. Europe also remains an important market because of its established clinical research infrastructure and substantial multinational study activity. The primary interviews conducted for this report can be categorized as follows: ・By Respondent: Supply Side - 70% and Demand Side - 30% ・By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 - 30% ・By Designation: CXOs and Directors - 30%, Managers - 45%, and Others - 25% ・By Region: North America - 35%, Europe - 25%, Asia Pacific - 20%, Latin America - 10%, the Middle East - 5%, and Africa - 5% List of Companies Profiled in the Report ・Thermo Fisher Scientific Inc. ・Almac Group ・Novo Holdings A/S (Catalent, Inc.) ・Marken (UPS) ・PCI Pharma Services ・Piramal Group ・Sharp Services LLC ・Cencora, Inc. ・Myonex ・Clinigen Limited ・Inceptua Group ・Eurofins Scientific ・Parexel International Corporation ・ICON plc ・IQVIA ・BioCair ・Lonza Research Coverage This research report categorizes the clinical trial supplies market by service, phase, type, therapeutic area, end user, and region. Services covered include logistics & distribution, packaging, labeling & blinding, storage & retention, manufacturing, comparator sourcing, and other services. The report assesses Phase I, Phase II, Phase III, Phase IV, and bioavailability/bioequivalence studies; small molecules, biologics, and medical devices; and major therapeutic areas. End users include pharmaceutical & biotechnology companies, CROs & CDMOs, and other organizations such as medical-device companies and academic & research institutes. The scope includes detailed analysis of market drivers, restraints, opportunities, and challenges. It also evaluates leading providers through their business overview, service portfolio, partnerships, acquisitions, expansions, agreements, and other recent developments associated with the clinical trial supplies market. Competitive analysis covers established players and emerging companies across the market ecosystem. Key Benefits of Buying the Report The report will help market leaders and new entrants by providing the closest approximations of revenue for the overall clinical trial supplies market and its subsegments. It will help stakeholders compare the competitive position and service capabilities of major providers and identify markets aligned with their expansion strategies. The report will also enable stakeholders to understand market demand across services, trial phases, therapy types, therapeutic areas, end users, and regions. It covers factors shaping growth, including clinical trial activity, supply-chain costs, decentralized trial models, digital supply technologies, drug shortages, and regulatory complexity. The report provides insights into the following pointers: ・Analysis of key drivers (growth in clinical trials and drug development, expansion of global and multicenter trials, and rising demand for personalized medicines and biologics), restraints (high costs associated with clinical trial supplies), opportunities (decentralized and virtual trials and the integration of digital supply-chain technologies), and challenges (supply-chain disruptions, drug shortages, and complex country-specific requirements) influencing the growth of the clinical trial supplies market ・Service Development/Innovation: Detailed insights into new and expanded clinical trial supply services, including comparator sourcing, direct-to-patient delivery, digital tracking, and cold-chain logistics ・Market Development: Comprehensive information about attractive markets and analysis of the clinical trial supplies market across North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa ・Market Diversification: Detailed information about new services, untapped geographies, recent developments, partnerships, acquisitions, capacity expansions, and investments in the clinical trial supplies market ・Competitive Assessment: In-depth assessment of market shares, growth strategies, and service portfolios of leading players such as Thermo Fisher Scientific Inc. (US), Almac Group (UK), Novo Holdings A/S (Catalent, Inc.) (Denmark/US), Marken (UPS) (US), and PCI Pharma Services (US), among others

ページTOPに戻る

Table of Contents

1 INTRODUCTION 42
1.1 STUDY OBJECTIVES 42
1.2 MARKET DEFINITION 42
1.3 MARKET SCOPE 43
1.3.1 MARKETS & REGIONS COVERED 43
1.3.2 INCLUSIONS & EXCLUSIONS 44
1.3.3 YEARS CONSIDERED 44
1.3.4 CURRENCY CONSIDERED 45
1.4 STAKEHOLDERS 45
1.5 SUMMARY OF CHANGES 45
2 EXECUTIVE SUMMARY 47
2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS 47
2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS 49
2.3 DISRUPTIVE TRENDS SHAPING THE MARKET 50
2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS 51
2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 52
3 PREMIUM INSIGHTS 53
3.1 CLINICAL TRIAL SUPPLIES MARKET OVERVIEW 53
3.2 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE AND COUNTRY (2025) 54
3.3 CLINICAL TRIAL SUPPLIES MARKET SHARE, BY TYPE, 2026 VS. 2031 54
3.4 CLINICAL TRIAL SUPPLIES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 55
4 MARKET OVERVIEW 56
4.1 INTRODUCTION 56
4.2 MARKET DYNAMICS 56
4.2.1 DRIVERS 57
4.2.1.1 Growth in clinical trials & drug development 57
4.2.1.2 Expansion of global and multicenter trials accelerating demand for clinical trial supplies 58
4.2.1.3 Rising demand for personalized medicine and biologics 58
4.2.2 RESTRAINTS 59
4.2.2.1 High costs associated with clinical trial supplies 59
4.2.3 OPPORTUNITIES 59
4.2.3.1 Rise in decentralized and virtual trials 59
4.2.3.2 Integration of digital technologies in supply chain management 60
4.2.4 CHALLENGES 60
4.2.4.1 Supply chain disruptions and drug shortages 60
4.3 UNMET NEEDS AND WHITE SPACES 61
4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES 61
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 62
5 INDUSTRY TRENDS 63
5.1 PORTER’S FIVE FORCES ANALYSIS 63
5.1.1 THREAT OF NEW ENTRANTS 64
5.1.2 BARGAINING POWER OF SUPPLIERS 64
5.1.3 BARGAINING POWER OF BUYERS 65
5.1.4 THREAT OF SUBSTITUTES 65
5.1.5 INTENSITY OF COMPETITIVE RIVALRY 65
5.2 MACROECONOMIC OUTLOOK 65
5.2.1 INTRODUCTION 65
5.2.2 GDP TRENDS AND FORECAST 66
5.2.3 TRENDS IN GLOBAL CLINICAL TRIAL SUPPLIES MARKET 66
5.3 VALUE CHAIN ANALYSIS 67
5.4 ECOSYSTEM ANALYSIS 69
5.4.1 CLINICAL TRIAL SUPPLIES MARKET: RAW MATERIAL PROVIDERS 69
5.4.2 CLINICAL TRIAL SUPPLIES MARKET: SERVICE PROVIDERS 70
5.4.3 CLINICAL TRIAL SUPPLIES MARKET: END USERS 70
5.4.4 CLINICAL TRIAL SUPPLIES MARKET: REGULATORY BODIES 71
5.5 PRICING ANALYSIS 71
5.5.1 AVERAGE SELLING PRICE, BY KEY PLAYER (QUALITATIVE) 71
5.5.2 INDICATIVE PRICE, BY SERVICE (QUALITATIVE) 72
5.6 INVESTMENT AND FUNDING SCENARIO 73
5.7 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 74
5.8 KEY CONFERENCES AND EVENTS, 2026–2027 75
5.9 IMPACT OF 2025 US TARIFFS—CLINICAL TRIAL SUPPLIES MARKET 76
5.9.1 INTRODUCTION 76
5.9.2 KEY TARIFF RATES 76
5.9.3 PRICE IMPACT ANALYSIS 76
5.9.4 IMPACT ON COUNTRIES/REGIONS 77
5.9.4.1 North America 77
5.9.4.1.1 US 77
5.9.4.2 Europe 77
5.9.4.3 Asia Pacific 78
5.9.5 IMPACT ON END-USE INDUSTRIES 78
5.9.5.1 Pharmaceutical & biotech companies 78
5.9.5.2 Medical devices companies 79
5.9.5.3 Academic institutes 79
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, INNOVATIONS AND FUTURE APPLICATIONS 80
6.1 TECHNOLOGY ANALYSIS 80
6.1.1 KEY TECHNOLOGIES 80
6.1.1.1 Serialization & track-and-trace technologies 80
6.1.1.2 Interactive response technology (IRT/IVR/IWR) 80
6.1.1.3 Cold chain & temperature monitoring solutions 80
6.1.2 COMPLEMENTARY TECHNOLOGIES 81
6.1.2.1 Artificial intelligence (AI) & machine learning (ML) 81
6.1.2.2 Blockchain for supply chain transparency 81
6.1.3 ADJACENT TECHNOLOGIES 81
6.1.3.1 Cryopreservation & advanced storage technologies 81
6.1.3.2 Advanced robotics in warehousing & distribution 81
6.2 TECHNOLOGY/PRODUCT ROADMAP 81
6.3 IMPACT OF AI/GEN AI ON CLINICAL TRIAL SUPPLIES MARKET 82
6.3.1 TOP USE CASES AND MARKET POTENTIAL 82
6.3.2 CASE STUDIES OF AI IMPLEMENTATION IN CLINICAL TRIAL SUPPLIES MARKET 83
6.3.3 INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS 83
6.3.4 CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN CLINICAL TRIAL SUPPLIES MARKET 84
7 REGULATORY LANDSCAPE 85
7.1 REGIONAL REGULATIONS AND COMPLIANCE 85
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 85
7.1.2 REGULATORY FRAMEWORK 88
7.1.2.1 North America 88
7.1.2.1.1 US 88
7.1.2.1.2 Canada 89
7.1.2.2 Europe 89
7.1.2.2.1 Germany 89
7.1.2.2.2 France 89
7.1.2.2.3 Italy 89
7.1.2.3 Asia Pacific 89
7.1.2.3.1 Japan 89
7.1.2.3.2 China 89
7.1.2.3.3 India 89
7.1.2.4 Latin America 90
7.1.2.4.1 Brazil 90
7.1.2.5 Middle East & Africa 90
7.1.2.5.1 GCC Countries 90
7.1.2.5.2 South Africa 90
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 91
8.1 DECISION-MAKING PROCESS 91
8.2 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA 92
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 92
8.2.2 KEY BUYING CRITERIA, BY END USER 93
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 94
8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 95
8.5 MARKET PROFITABILITY 95
9 CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE 97
9.1 INTRODUCTION 98
9.2 LOGISTICS & DISTRIBUTION SERVICES 98
9.2.1 RISING DEMAND DUE TO INCREASING EMPHASIS ON CLINICAL DIAGNOSTICS TO SUPPORT MARKET GROWTH 98
9.3 STORAGE & RETENTION SERVICES 102
9.3.1 RISING DEMAND FOR ULTRA-LOW-TEMPERATURE STORAGE TO DRIVE GROWTH 102
9.4 PACKAGING, LABELING, AND BLINDING SERVICES 105
9.4.1 PRIMARY PACKAGING SERVICES 109
9.4.1.1 Increasing demand for innovative drug formulations to support market growth 109
9.4.2 SECONDARY PACKAGING SERVICES 112
9.4.2.1 Increasing complexity of global clinical trials to propel market 112
9.4.3 LABELING & BLINDING SERVICES 115
9.4.3.1 Rising number of randomized and double-blind studies to propel market 115
9.5 MANUFACTURING SERVICES 118
9.5.1 RISING COMPLEXITY OF TRIALS, DEMAND FOR BIOLOGICS, AND RELIANCE ON CDMOS TO DRIVE MARKET 118
9.6 COMPARATOR SOURCING SERVICES 121
9.6.1 RISING DEMAND FOR COMPARATOR SOURCING TO DRIVE MARKET 121
9.7 OTHER SERVICES 125
10 CLINICAL TRIAL SUPPLIES MARKET, BY PHASE 129
10.1 INTRODUCTION 130
10.2 PHASE III 130
10.2.1 DEVELOPMENT OF BIOLOGICS AND ADVANCED THERAPIES TO SUPPORT MARKET GROWTH 130
10.3 PHASE II 134
10.3.1 NEED FOR GREATER EFFICIENCY AND COMPLIANCE IN TRIAL LOGISTICS TO SUPPORT MARKET GROWTH 134
10.4 PHASE I 137
10.4.1 RISING COMPLEXITY OF INVESTIGATIONAL DRUGS TO DRIVE MARKET GROWTH 137
10.5 PHASE IV 141
10.5.1 INCREASING FOCUS ON PATIENT-CENTRIC APPROACHES TO DRIVE MARKET GROWTH 141
10.6 PHASE BA/BE 144
10.6.1 ACCELERATING GENERIC DRUG APPROVALS THROUGH OPTIMIZED BA/BE STUDIES TO SUPPORT MARKET GROWTH 144
11 CLINICAL TRIAL SUPPLIES MARKET, BY TYPE 148
11.1 INTRODUCTION 149
11.2 SMALL MOLECULES 149
11.2.1 HIGH VOLUME OF SMALL-MOLECULE CLINICAL TRIALS 149
11.3 BIOLOGICS 153
11.3.1 MONOCLONAL ANTIBODIES 157
11.3.1.1 Rising demand for monoclonal antibodies to drive growth 157
11.3.2 VACCINES 160
11.3.2.1 Increased focus on development of novel vaccines to drive growth 160
11.3.3 OTHER BIOLOGICS 164
11.4 MEDICAL DEVICES 167
11.4.1 RISING DEMAND FOR SPECIALIZED LOGISTICS IN MEDICAL DEVICE CLINICAL TRIALS TO DRIVE MARKET GROWTH 167
12 CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA 171
12.1 INTRODUCTION 172
12.2 ONCOLOGY 173
12.2.1 RISING DISEASE BURDEN TO SUPPORT MARKET GROWTH 173
12.3 NEUROLOGY 177
12.3.1 INCREASING R&D INVESTMENT TO SUPPORT MARKET GROWTH 177
12.4 RESPIRATORY DISORDERS 181
12.4.1 RISING INCIDENCE OF RESPIRATORY DISORDERS TO SUPPORT MARKET GROWTH 181
12.5 METABOLIC DISORDERS/ENDOCRINOLOGY 184
12.5.1 INCREASING GLOBAL DIABETES POPULATION TO SUPPORT MARKET GROWTH 184
12.6 CARDIOVASCULAR SYSTEM DISORDERS 188
12.6.1 RISING DEMAND IN CLINICAL DIAGNOSTICS TO PROPEL MARKET GROWTH 188
12.7 DERMATOLOGY 191
12.7.1 GROWING FOCUS ON DRUG DEVELOPMENT TO SUPPORT MARKET GROWTH 191
12.8 GASTROINTESTINAL SYSTEM DISORDERS 195
12.8.1 INCREASING INCIDENCE OF LIFESTYLE AND DIETARY RISK FACTORS TO DRIVE DEMAND 195
12.9 IMMUNOLOGIC DISORDERS 198
12.9.1 GROWING CLINICAL RESEARCH TO SUPPORT MARKET GROWTH 198
12.10 INFECTIOUS DISEASES 202
12.10.1 RISING OUTBREAKS OF INFECTIOUS DISEASES TO SUPPORT MARKET GROWTH 202
12.11 PSYCHIATRY 206
12.11.1 RISING INCIDENCE OF PSYCHIATRIC DISORDERS TO PROPEL MARKET GROWTH 206
12.12 OPHTHALMOLOGY 209
12.12.1 RISING NUMBER OF OPHTHALMIC PIPELINE DRUGS TO AID MARKET GROWTH 209
12.13 HEMATOLOGY 213
12.13.1 INTEGRATION OF ADVANCED SUPPLY CHAIN TECHNOLOGIES TO FUEL MARKET GROWTH 213
12.14 GENITOURINARY & WOMEN’S HEALTH 216
12.14.1 RISING PREVALENCE OF CHRONIC DISORDERS IN WOMEN TO PROPEL MARKET GROWTH 216
12.15 OTHER THERAPEUTIC AREAS 220
13 CLINICAL TRIAL SUPPLIES MARKET, BY END USER 224
13.1 INTRODUCTION 225
13.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 225
13.2.1 EXPANDING R&D PIPELINES AND INCREASING TRIAL COMPLEXITY TO DRIVE DEMAND FOR CLINICAL TRIAL SUPPLIES 225
13.3 CROS 229
13.3.1 INCREASING INTEGRATION OF CLINICAL OPERATIONS AND SUPPLY CHAIN MANAGEMENT TO DRIVE MARKET GROWTH 229
13.4 MEDICAL DEVICE COMPANIES 232
13.4.1 RISING CLINICAL EVIDENCE REQUIREMENTS AND DEVICE INNOVATION TO DRIVE DEMAND FOR CLINICAL TRIAL SUPPLIES 232
14 CLINICAL TRIAL SUPPLIES MARKET, BY REGION 236
14.1 INTRODUCTION 237
14.2 NORTH AMERICA 237
14.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 238
14.2.2 US 243
14.2.2.1 Robust hospital infrastructure and drug research & development to stimulate growth 243
14.2.3 CANADA 246
14.2.3.1 Growing preference of pharmaceutical companies to conduct trials to favor growth 246
14.3 EUROPE 250
14.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 250
14.3.2 GERMANY 255
14.3.2.1 Growing focus on reducing approval timelines and high spending by global pharmaceutical players to propel market 255
14.3.3 UK 259
14.3.3.1 Expanding tax credits to encourage growth 259
14.3.4 FRANCE 262
14.3.4.1 Evolving regulatory landscape to stimulate growth 262
14.3.5 ITALY 266
14.3.5.1 Increasing number of drug approvals to accelerate growth 266
14.3.6 SPAIN 269
14.3.6.1 Favorable clinical trial network in public health system to sustain growth 269
14.3.7 SWITZERLAND 272
14.3.7.1 Presence of multinational corporations and small and medium-sized pharmaceutical companies to fuel market 272
14.3.8 NETHERLANDS 276
14.3.8.1 Increasing collaborations among pharmaceutical giants to promote growth 276
14.3.9 REST OF EUROPE 279
14.4 ASIA PACIFIC 283
14.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 283
14.4.2 CHINA 288
14.4.2.1 High proportion of domestic industry-sponsored trials to speed up growth 288
14.4.3 JAPAN 292
14.4.3.1 Increasing focus on lowering regulatory timelines to facilitate growth 292
14.4.4 INDIA 295
14.4.4.1 Rise in early-phase clinical trials to spur growth 295
14.4.5 AUSTRALIA 299
14.4.5.1 Increasing research funding to favor growth 299
14.4.6 SOUTH KOREA 302
14.4.6.1 Growing focus on new drug development research to drive market 302
14.4.7 SINGAPORE 306
14.4.7.1 Advanced research facilities to intensify growth 306
14.4.8 REST OF ASIA PACIFIC 309
14.5 LATIN AMERICA 313
14.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 313
14.5.2 BRAZIL 317
14.5.2.1 Regulatory improvements to support growth 317
14.5.3 MEXICO 321
14.5.3.1 Expanding landscape of clinical trials to boost market 321
14.5.4 REST OF LATIN AMERICA 324
14.6 MIDDLE EAST 327
14.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST 327
14.6.2 GCC COUNTRIES 332
14.6.2.1 Saudi Arabia 335
14.6.2.1.1 Booming investments in research infrastructure and life sciences development to aid growth 335
14.6.2.2 UAE 339
14.6.2.2.1 Increasing public-private partnerships and genomic research initiatives to augment growth 339
14.6.2.3 Rest of GCC Countries 342
14.6.3 REST OF MIDDLE EAST 345
14.7 AFRICA 348
14.7.1 GROWING DEMAND FOR OUTSOURCING SERVICES TO DRIVE MARKET GROWTH 348
14.7.2 MACROECONOMIC OUTLOOK FOR AFRICA 349
15 COMPETITIVE LANDSCAPE 353
15.1 INTRODUCTION 353
15.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 353
15.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN CLINICAL TRIAL SUPPLIES MARKET 353
15.3 REVENUE ANALYSIS, 2023–2025 355
15.4 MARKET SHARE ANALYSIS, 2025 356
15.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 358
15.5.1 STARS 358
15.5.2 EMERGING LEADERS 358
15.5.3 PERVASIVE PLAYERS 358
15.5.4 PARTICIPANTS 358
15.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 360
15.5.5.1 Company footprint 360
15.5.5.2 Region footprint 360
15.5.5.3 Service footprint 361
15.5.5.4 Type footprint 362
15.5.5.5 End-user footprint 363
15.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 364
15.6.1 PROGRESSIVE COMPANIES 364
15.6.2 RESPONSIVE COMPANIES 364
15.6.3 DYNAMIC COMPANIES 364
15.6.4 STARTING BLOCKS 364
15.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025 366
15.6.5.1 Detailed list of key startups/SMEs 366
15.6.5.2 Competitive benchmarking of key startups/SMEs 367
15.7 COMPANY VALUATION & FINANCIAL METRICS 368
15.7.1 COMPANY VALUATION 368
15.7.2 FINANCIAL METRICS 368
15.8 BRAND/SERVICE COMPARISON 369
15.9 COMPETITIVE SCENARIO 370
15.9.1 DEALS 370
15.9.2 EXPANSIONS 370
16 COMPANY PROFILES 372
16.1 KEY PLAYERS 372
16.1.1 THERMO FISHER SCIENTIFIC INC. 372
16.1.1.1 Business overview 372
16.1.1.2 Services offered 373
16.1.1.3 Recent developments 374
16.1.1.3.1 Service launches 374
16.1.1.3.2 Expansions 375
16.1.1.4 MnM view 375
16.1.1.4.1 Right to win 375
16.1.1.4.2 Strategic choices 375
16.1.1.4.3 Weaknesses & competitive threats 376
16.1.2 NOVO HOLDINGS A/S (CATALENT, INC.) 377
16.1.2.1 Business overview 377
16.1.2.2 Services offered 378
16.1.2.3 Recent developments 379
16.1.2.3.1 Deals 379
16.1.2.3.2 Expansions 380
16.1.2.4 MnM view 380
16.1.2.4.1 Right to win 380
16.1.2.4.2 Strategic choices 380
16.1.2.4.3 Weaknesses & competitive threats 380
16.1.3 UNITED PARCEL SERVICE OF AMERICA, INC. 381
16.1.3.1 Business overview 381
16.1.3.2 Services offered 382
16.1.3.3 Recent developments 383
16.1.3.3.1 Deals 383
16.1.3.3.2 Expansions 383
16.1.3.4 MnM view 384
16.1.3.4.1 Right to win 384
16.1.3.4.2 Strategic choices 384
16.1.3.4.3 Weaknesses & competitive threats 384
16.1.4 EUROFINS SCIENTIFIC 385
16.1.4.1 Business overview 385
16.1.4.2 Services offered 386
16.1.4.3 Recent developments 387
16.1.4.3.1 Expansions 387
16.1.4.3.2 Other developments 388
16.1.4.4 MnM view 388
16.1.4.4.1 Right to win 388
16.1.4.4.2 Strategic choices 388
16.1.4.4.3 Weaknesses & competitive threats 388
16.1.5 PIRAMAL PHARMA LIMITED 389
16.1.5.1 Business overview 389
16.1.5.2 Services offered 390
16.1.5.3 Recent developments 391
16.1.5.3.1 Deals 391
16.1.5.3.2 Expansions 391
16.1.5.4 MnM view 392
16.1.5.4.1 Right to win 392
16.1.5.4.2 Strategic choices 392
16.1.5.4.3 Weaknesses & competitive threats 392
16.1.6 IQVIA 393
16.1.6.1 Business overview 393
16.1.6.2 Services offered 395
16.1.7 ICON PLC 396
16.1.7.1 Business overview 396
16.1.7.2 Services offered 397
16.1.7.3 Recent developments 398
16.1.7.3.1 Service launches 398
16.1.7.3.2 Deals 398
16.1.8 LONZA 399
16.1.8.1 Business overview 399
16.1.8.2 Services offered 400
16.1.8.3 Recent developments 400
16.1.8.3.1 Deals 400
16.1.8.3.2 Expansions 401
16.1.9 UNIPHAR GROUP PLC 402
16.1.9.1 Business overview 402
16.1.9.2 Services offered 403
16.1.9.3 Recent developments 404
16.1.9.3.1 Deals 404
16.1.9.3.2 Expansions 404
16.1.10 ALMAC GROUP 405
16.1.10.1 Business overview 405
16.1.10.2 Services offered 405
16.1.10.3 Recent developments 406
16.1.10.3.1 Service launches 406
16.1.10.3.2 Expansions 406
16.1.11 SHARP SERVICES, LLC 407
16.1.11.1 Business overview 407
16.1.11.2 Services offered 407
16.1.11.3 Recent developments 408
16.1.11.3.1 Deals 408
16.1.11.3.2 Expansions 409
16.1.12 PCI PHARMA SERVICES 410
16.1.12.1 Business overview 410
16.1.12.2 Services offered 410
16.1.12.3 Recent developments 411
16.1.12.3.1 Deals 411
16.1.12.3.2 Expansions 411
16.1.13 PAREXEL INTERNATIONAL (MA) CORPORATION 413
16.1.13.1 Business overview 413
16.1.13.2 Services offered 413
16.1.14 BIOCAIR 414
16.1.14.1 Business overview 414
16.1.14.2 Services offered 414
16.2 OTHER PLAYERS 415
16.2.1 CENCORA, INC. 415
16.2.2 CLINIGEN LIMITED 416
16.2.3 KLIFO 417
16.2.4 IPS PHARMA 418
16.2.5 COREX LOGISTICS LIMITED 419
16.2.6 OCT GROUP LLC 420
16.2.7 MYONEX 421
16.2.8 INCEPTUA GROUP 422
16.2.9 ANCILLARE, LP 423
16.2.10 ADALLEN PHARMA 424
16.2.11 CLINICAL SERVICES INTERNATIONAL (CSI) 425
16.2.12 NUVISAN GMBH 426
16.2.13 AENOVA HOLDING GMBH 427
17 RESEARCH METHODOLOGY 428
17.1 RESEARCH DATA 428
17.1.1 SECONDARY DATA 429
17.1.2 PRIMARY RESEARCH 430
17.2 MARKET SIZE ESTIMATION 431
17.2.1 GLOBAL MARKET ESTIMATION 431
17.2.1.1 Insights from primary experts 433
17.2.2 SEGMENTAL MARKET ESTIMATION (TOP-DOWN APPROACH) 434
17.3 MARKET GROWTH RATE PROJECTIONS 435
17.4 DATA TRIANGULATION 438
17.5 RESEARCH ASSUMPTIONS 439
17.6 RESEARCH LIMITATIONS 440
17.7 RISK ANALYSIS 440
18 APPENDIX 441
18.1 DISCUSSION GUIDE 441
18.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 445
18.3 CUSTOMIZATION OPTIONS 447
18.4 RELATED REPORTS 447
18.5 AUTHOR DETAILS 448